Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.
about
In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infectionPharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infectionComparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.Vancomycin revisited - 60 years laterIn vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptidesIn vivo pharmacodynamic activity of the glycopeptide dalbavancinSetting and revising antibacterial susceptibility breakpoints.Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infectionComparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.Development of methionyl-tRNA synthetase inhibitors as antibiotics for Gram-positive bacterial infections.
P2860
Q33559139-19C4AECF-D471-480F-8468-6E6619D421EAQ33622963-A818BDE1-C171-4C4E-A685-30B6C3239960Q33979426-06F2890C-132B-4168-868E-6F5AE44577D7Q34309620-7D8F3898-1774-4BF1-899A-746EFBE4D06FQ34433066-D281A8E5-6A67-4BE4-889F-3AA098C94795Q34824344-AD519447-1FED-4BE8-948F-19C128A8ADA8Q35083990-E8EA0990-F44A-4F47-AB69-7222B236F37DQ35759076-8F70EB78-788A-44ED-A2B1-1A74C4CFB5BCQ35913176-A5EA5BEC-DB7A-4777-BD22-3487E04F6DE3Q36292752-8F460741-C179-4675-A39A-5AEA7C3F3586Q38833633-1A34BFF6-9D91-4A8C-AA71-B136FEB3C388Q38898264-8BD91384-FEAF-40A8-BDEE-55FCD811AF3EQ40077119-2BF4FCBD-BBEC-42C5-A1FE-8637059A20BA
P2860
Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Activities of vancomycin and t ...... n the mouse peritonitis model.
@ast
Activities of vancomycin and t ...... n the mouse peritonitis model.
@en
type
label
Activities of vancomycin and t ...... n the mouse peritonitis model.
@ast
Activities of vancomycin and t ...... n the mouse peritonitis model.
@en
prefLabel
Activities of vancomycin and t ...... n the mouse peritonitis model.
@ast
Activities of vancomycin and t ...... n the mouse peritonitis model.
@en
P2093
P2860
P356
P1476
Activities of vancomycin and t ...... in the mouse peritonitis model
@en
P2093
Espersen F
Frimodt-Møller N
Fuursted K
Knudsen JD
P2860
P304
P356
10.1128/AAC.41.9.1910
P407
P577
1997-09-01T00:00:00Z